FDA Draft guidance on Good ANDA Submission Practices [Regulatives / Guidelines]

posted by BRB  – Canada, 2018-01-03 22:42 (2392 d 17:42 ago) – Posting: # 18137
Views: 1,672

Hi all,

The FDA just posted a draft guidance on Good ANDA submission practices:


I found the section on deviations from product-specific guidances to be rather interesting such as:

A detailed justification for and data (such as their inclusion/exclusion criteria or demographic information) to support why their use of a particular study population does not affect their BE determination.

So for imatinib BE studies, which have been done in healthy subjects, but the guidance recommends to use patients, a detailed justification now needs to be provided?


Complete thread:

UA Flag
 Admin contact
23,119 posts in 4,859 threads, 1,647 registered users;
41 visitors (1 registered, 40 guests [including 8 identified bots]).
Forum time: 17:25 CEST (Europe/Vienna)

You can’t really say “similar” if it’s the same again you want.
“Similar” means something different.    Anthony Burgess

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz